Literature DB >> 27575450

Comparison of three different doses sugammadex based on ideal body weight for reversal of moderate rocuronium-induced neuromuscular blockade in laparoscopic bariatric surgery.

Ahmad M Abd El-Rahman1, Ahmed H Othman1, Fatma A El Sherif2, Mohamed F Mostafa3, Osama Taha4.   

Abstract

BACKGROUND: The majority of authors and the literature recommend sugammadex dose to be calculated according to RBW without taking fat content into consideration. Our aim was to compare the efficacy and safety of sugammadex at doses of 1.5, 2, and 4 mg/kg, calculated according to ideal body weight basis, for the reversal of moderate rocuronium-induced neuromuscular blockade in laparoscopic bariatric surgery.
METHODS: One-hundred and eighty morbidly obese patients were randomly assigned into three groups according to sugammadex dose administrated (based on IBW after reaching T2 of TOF): Group I: patients were given 1.5 mg/kg. Group II: patients were given 2 mg/kg. Group III: patients were given 4 mg/kg. Both sugammadex and extubation times were recorded.
RESULTS: Sugammadex time was significantly longer in groups I and II versus III (P=0.000, 0.005 respectively). Difference between groups I and II was insignificant. The extubation time was insignificantly different in the three groups (P>0.05).
CONCLUSIONS: A dose of sugammadex of 1.5 mg/kg calculated according to IBW successfully reversed moderate rocuronium-induced NMB in laparoscopic bariatric surgeries.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27575450     DOI: 10.23736/S0375-9393.16.11349-5

Source DB:  PubMed          Journal:  Minerva Anestesiol        ISSN: 0375-9393            Impact factor:   3.051


  4 in total

Review 1.  Peri-operative Medication Dosing in Adult Obese Elective Surgical Patients: A Systematic Review of Clinical Studies.

Authors:  Zahid Hussain; Colin Curtain; Corinne Mirkazemi; Syed Tabish Razi Zaidi
Journal:  Clin Drug Investig       Date:  2018-08       Impact factor: 2.859

Review 2.  Preparing for the unexpected: special considerations and complications after sugammadex administration.

Authors:  Hajime Iwasaki; J Ross Renew; Takayuki Kunisawa; Sorin J Brull
Journal:  BMC Anesthesiol       Date:  2017-10-17       Impact factor: 2.217

3.  Efficacy and safety of sugammadex doses calculated on the basis of corrected body weight and total body weight for the reversal of deep neuromuscular blockade in morbidly obese patients.

Authors:  Deming Li; Yuanyuan Wang; Yong Zhou; Chunming Yin
Journal:  J Int Med Res       Date:  2021-01       Impact factor: 1.671

Review 4.  Advantages and pitfalls of clinical application of sugammadex.

Authors:  Hyung Young Lee; Ki Tae Jung
Journal:  Anesth Pain Med (Seoul)       Date:  2020-07-31
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.